The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment

Topçu, Yasemin; Kurul, Semra Hız; Bayram, Erhan; Sözmen, Kaan; Yış, Uluç

doi:10.1111/apa.12752

Cited by 14 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pediatric migraine, which can affect the children's school performances and quality of life (8,9), has become a significant problem for children. Most researchers (10) believe that if migraine has more than three to four episodes per month or the attack causes significant disability, which can be measured by the Pediatric Migraine Disability Assessment Scale (PedMIDAS) (11,12), then preventive treatment for migraine needs to be initiated (13). Management of pediatric migraine includes treatment of acute headache attack and preventive treatment.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis

Zhang

Lü

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

Background: Migraine is the most common acute primary headache in children and adolescents. In 2014, topiramate became the first preventive drug for migraine, approved by the Food and Drug Administration (FDA) for adolescents. This meta-analysis was aimed to evaluate the efficacy and safety of topiramate in the prevention of pediatric migraine. Methods: We searched the PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure (CNKI) databases up to June 2019 for eligible randomized controlled trials (RCTs). The primary outcomes were mean migraine days per month, ≥50% reduction rate, and Pediatric Migraine Disability Assessment Scale (PedMIDAS) scores. RevMan5.3 software was performed for statistical analysis. Results: Overall, 5 RCTs recruiting 531 patients (6-17 years of age) were included in the meta-analysis. The target dose of topiramate was 2 mg/kg (the maintenance phase was 12 weeks), 2-3 mg/kg, 50 mg/day, and 100 mg/day (maintaining for 16 weeks), respectively, in the included studies. Our results demonstrate that participants receiving topiramate had a significant advantage in remitting the monthly migraine days than those receiving placebo, with a mean difference (MD) of −0.78 (n = 531; 95% CI, −1.23 to −0.32; Z = 3.37; P = 0.0008). Topiramate could also reduce the mean PedMIDAS scores (n = 238; 95% CI, −16.53 to −0.49; Z = 2.43; P = 0.04). However, there was no significant difference in the percentage of patients experiencing a ≥50% reduction in monthly headache days between topiramate and placebo groups (n = 531; 95% CI, 0.94-1.77; Z = 1.58; P = 0.11). Topiramate was associated with higher rates of side effects such as weight decrease (n = 395; 95% CI, 2.73-22.98; Z = 3.81; P < 0.01) and paresthesia (n = 531; 95% CI, 3.05-13.18; Z = 4.94; P < 0.01). Conclusions: Topiramate can significantly decrease monthly headache days and migraine-related burden in migraine patients <18 years old. However, it failed to increase 50% response rate. Adverse events seem to be more frequent in topiramate-treated children.

show abstract

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis

Zhang

Lü

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…This questionnaire has been used in clinical practice, in observational studies and clinical trials . It can be used to assess initial disability as well as monitor improvement with treatment over time .…”

Section: Introductionmentioning

confidence: 99%

“…6,7 This questionnaire has been used in clinical practice, in observational studies and clinical trials. [8][9][10] It can be used to assess initial disability as well as monitor improvement with treatment over time. 7 PedMIDAS is a subjective assessment of disability based on the patient's perception and, therefore, responds to perceived and expected response patterns of treatment.…”

Section: Introductionmentioning

confidence: 99%

Pediatric Migraine Disability Assessment (PedMIDAS): Translation Into Brazilian Portuguese and Cross‐Cultural Adaptation

Rocha-Filho

Hershey

2017

Headache

View full text Add to dashboard Cite

show abstract

“…Headache needs appropriate and full assessment of family history, physical, psychological, and neurological examination, with appropriate diagnostic testing. Full assessment will enable the physician to detect correctly the cause and type of headache (Jan, 2007; Lima et al, 2014; Topcu, Hiz, Bayram, Sozmen, & Yis, 2014).…”

mentioning

confidence: 99%

Assessment of Headache Among High School Students in Jordan

ALBashtawy

Qadire

Aloush

et al. 2017

The Journal of School Nursing

View full text Add to dashboard Cite

Headache is considered one of the most common complaints affecting all ages: children, adolescents, and adults. A school-based, cross-sectional study was conducted to assess primary headache among high school students aged 16-18 in Grades 11-12, over a period of 3 weeks (May 2017). A questionnaire was designed, in accordance with the International Headache Society's criteria. The Pearson's χ test was computed to show the differences between the variables. Nearly two thirds of the students reported having headache (19.0% tension-type headache, 8.8% migraine, and 39.0% unknown type). Nearly a quarter sought help for headache, and the most frequently used analgesic was acetaminophen (82.2%) followed by aspirin (5.1%). The current study revealed that the prevalence of headache and migraine was initially high and increased with age. Moreover, headache is one of the major public health problems among high school students. An education program conducted by school nurses and other health-care providers regarding headache and migraine is needed.

show abstract

The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment

Abstract: The PedMIDAS scoring system is useful in evaluating the efficacy of prophylactic therapy in paediatric migraine. Topiramate and propranolol lowered the PedMIDASs better than flunarizine.

Cited by 14 publications

References 17 publications

The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis

The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis

Pediatric Migraine Disability Assessment (PedMIDAS): Translation Into Brazilian Portuguese and Cross‐Cultural Adaptation

Assessment of Headache Among High School Students in Jordan

Contact Info

Product

Resources

About